Nutra Pharma Q2 FY26 net loss widens to $3.95 million; net sales drop 59.23% to $57,922

• Nutra Pharma posted a net loss of $3.95 million for the quarter ended June 30, 2026, swinging from net income of $369,577.
• Net sales fell 59.23% to $34,463 versus the prior-year quarter, reflecting product lines transitioned to Avini Health and lower private-label orders.
• Operating expenses rose 32.24% to $468,089 on higher consulting and professional fees tied to SEC filing and tax-return catch-up work.
• Derivative-related fair-value changes produced a $3.41 million loss, versus a $704,622 gain a year earlier, as hybrid-instrument liabilities fluctuated.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutra Pharma Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-039166), on August 19, 2026, and is solely responsible for the information contained therein.